

4.0.3 DOC Cmte minutes

Parkinson's disease guideline committee meeting

Date: 10/03/16 & 11/03/16

Location: Manchester Central Library

Minutes: Final

Committee members present:		
	Day 1	Day 2
Paul Cooper (Chair)	Present for all	Present for all
Janine Barnes (JB)	Present for all	Present for all
Ivan Bennett (IB)	Present for all	Present for all
Alistair Church (AC)	Present for all	Present for all
Julian Evans (JE)	Present for all	Present for all
Robin Fackrell (RF)	Present for items 5-8	Present for all
Richard Grunewald (RG)	Present for all	Present for all
Graham Lennox (GL)	Present for all	Present for all
Fiona Lindop (FL)	Present for all	Present for all
Jane Little (JL)	Present for all	Present for all
Lynne Osbourne (LO)	Present for all	Present for all
Matthew Sullivan (MS)	Present for all	Present for all
Richard Walker (RW)	Present for all	Present for items 1-4
Nicholas Miller (NM) (co-opted)	Present for all	Present for all

In attendance:			
		Day 1	Day 2
Caroline Rick	Expert Advisor – University of Birmingham	Present for item 3	Did not attend

4.0.3 DOC Cmte minutes

Adrian Williams	Expert Advisor – University of Birmingham	Present for item 3	Did not attend
Gabriel Rogers (GR)	Technical Adviser – Health Economics	Present for all	Present for all
Steven Ward (SW)	Health Economist	Present for all	Present for all
Sue Spiers (SS)	Associate Director	Present for items 4-8	Present for all
Sarah Mills (SM)	Project Manager	Present for all	Present for all
Kate Moring (KM)	Business Analyst	Present for all	Did not attend
Louise Bate (LB)	Associate Director – Medicines Education	Present for items 4-6	Did not attend
Louise Picton (LP)	Analyst – Medicines Prescribing Centre	Present for all	Present for all
Ben Doak (BD)	NICE Commissioning Manager	Present for all	Present for items 1-4
Joshua Pink (JP)	Technical Advisor	Present for all	Present for all

Observers:

Yingying Wang	ICG – Technical Analyst
Wendy Gideman	NICE – ODU Health Economist

Committee member apologies:

Debbie Davis
Paul Shotbolt

Thursday 10 March 2016

1. Welcome, introductions, minutes, Dol and matters arising

The Chair welcomed the Committee members and attendees to the tenth meeting on Parkinson's disease.

The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts.

Name	Declaration	Classification	Chairs action
------	-------------	----------------	---------------

4.0.3 DOC Cmte minutes

Richard Walker	Brittania sponsored attendance at Movement Disorders Conference in Berlin in June 2016	Specific, personal, financial (within NICE expense limit)	Declare and participate
Janine Barnes	Attendance at advisory board meeting arranged by Verto Health Consulting Ltd. Regarding a new MAOB inhibitor Safinamide. No honorarium received	Specific, personal, financial (within NICE expense limit)	Declare and participate
Janine Barnes	Attendance at advisory board meeting organised by Simon Kucher & Partners regarding a new clinical Apomorphine formulation. No honorarium received	Specific, personal, financial (within NICE expense limit)	Declare and participate
Lynne Osborne	Attended pharmaceutical meeting (PINK) sponsored by Britannia Pharma.	Non-specific, personal, non-financial	Declare and participate
Lynne Osborne	Facilitating a South West Parkinson's Nurse Specialist meeting sponsored by a selection of pharma companies.	Non-specific, personal, non-financial	Declare and participate
Robin Frackell	BIAL sponsored attendance at Movement Disorders Conference in	Specific, personal, financial (within in NICE expense limit)	Declare and participate

4.0.3 DOC Cmte minutes

	Berlin in June 2016		
<p>It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.</p> <p>The committee reviewed the minutes of the previous meeting and agreed they were an accurate record of the discussions.</p> <p>PC confirmed that the main objectives for the two day were to consider evidence from the expert witnesses and consider clinical and economic data for review questions 15, 16, 17, 18.</p>			
<p>2.Resource impact guidelines</p>			
<p>PC provided an overview of NICE’s policy with regard to consideration of resource impact when making guideline recommendations and how this may affect the recommendations within the Parkinson’s Disease guideline.</p>			
<p>RQ20 Prioritisation of outcomes (originally scheduled as Day 2 Item 4)</p>			
<p>LP provided the committee with information regarding the range of published outcomes for review question 20. The committee considered these and prioritised outcomes based on their clinical usefulness.</p>			
<p>3. Expert Advisors – PD Surg RCT</p>			
<p>The Chair introduced CR and AW who provided an overview of the conduct and outcome from the PD Surg trial of DBS for people with Parkinson’s Disease. CR and AW responded to questions from the committee.</p>			
<p>4 and 5. Clinical data for review questions 15, 17 & 18</p>			
<p>JP and GR presented the clinical evidence for review questions 15, 17 and 19. The evidence was discussed by the committee. The committee considered and discussed the evidence but deferred making any recommendations until they had been presented with the health economic evidence supporting these review questions.</p>			
<p>6. Existing health economic evidence for questions 15, 17, 18</p>			
<p>SW presented data relating to existing, published health economic evaluations relating to review questions 15, 17 and 18. The committee discussed the merits of these analyses and their ability to inform their decision making.</p>			
<p>7. Health economic model for questions 15, 17, 18</p>			
<p>SW presented the de novo health economic model developed to address review</p>			

4.0.3 DOC Cmte minutes

questions 15, 17 and 18. The committee provided input to a number of parameters within the model and it was agreed that these would be incorporated and the model represented at day 2 of the meeting.

8. AOB

PC summarised the day and noted the discussions that would be continued during day 2.

Friday 11 March 2016

1. Health economic model for questions 15, 17, 18 (continued)

SW represented the health economic model for review questions 15, 17 and 18 having taken into account the discussions and input from committee members during day 1.

2 and 3. Discussion and recommendations for questions 15, 17, 18

The committee considered the evidence presented including the health economic modelling and made a number of recommendations in this area.

4. RQ20 Prioritisation of outcomes (please note that this item was discussed during day 1)

5 and 6. Clinical data, existing health economic evidence and recommendations for review questions 16

JP and GR presented clinical evidence relating to review question 16. SW presented data relating to existing, published health economic evaluations relating to review questions 16. The committee discussed the evidence provided and considered the need and the ability for the evidence to support recommendations in this area.

6. AOB

PC thanked the committee and summarised the outcome of the meeting. It was noted that the next meeting will be on Monday 18 April in Manchester.